Return to search results
Obiltoxaximab
Anthim (obiltoxaximab) is a prescription monoclonal antibody used to treat inhalation anthrax in combination with antibiotics. It's administered intravenously as a single-dose injection. Manufactured by Elusys Therapeutics, Inc., it was approved by the FDA in 2016. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Anthim (obiltoxaximab) is a prescription monoclonal antibody used to treat inhalation anthrax in combination with antibiotics. It's administered intravenously as a single-dose injection. Manufactured by Elusys Therapeutics, Inc., it was approved by the FDA in 2016. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Obiltoxaximab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Obiltoxaximab — ANDA 125509 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125509"
}
]
|
| identifier | ANDA125509 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"health-care",
"pharmaceuticals",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Obiltoxaximab |
